Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03325010 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette Syndrome

Interventions

DRUG: Valbenazine
DRUG: Placebo oral capsule

Sponsor

Neurocrine Biosciences